undamentalytics Newsletter
Sign in

Biodexa Pharmaceuticals plc revenue

Biodexa Pharmaceuticals plc's revenue was $473,962 in fiscal 2023, down 45.2% on the year before. Since fiscal 2015 ($2.1m) it has grown at a compound -17.0% a year.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 2023
Revenue2,1021,7931,2752,590861440796865474
Growth on the year before—−14.7%−28.9%+103.1%−66.8%−48.9%+80.8%+8.7%−45.2%
Gross profit1,9958,4808,600——————
Gross margin94.9%————————

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Biodexa Pharmaceuticals plc $473,962 -45.2% —
Cardiff Oncology, Inc. $508,000 -7.0% 7.2%
Cervomed Inc. $331,295 -95.7% -52.7%
Medicinova Inc $920,481 875.7% —
Shattuck Labs, Inc. $1.0m -66.6% 5.2%
Clene Inc. $197,000 -31.1% -36.9%

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Biodexa Pharmaceuticals plc's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biodexa Pharmaceuticals plc.